Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival

Division of Cardiology, University of Connecticut Health Center, Farmington 06030, USA.

OBJECTIVES. We attempted to determine whether a family history of severe cardiovascular disease in patients with the Marfan syndrome is associated with increased aortic dilation or decreased survival, or both. BACKGROUND. The prognostic importance of a family history of severe cardiovascular disease in patients with the Marfan syndrome has been incompletely examined. We hypothesized that such a family history would correlate with increased aortic dilation and would be associated with decreased survival. METHODS. One hundred eight affected patients and 48 unaffected family members from 33 multigenerational families with the Marfan syndrome underwent echocardiographic measurement of the aortic root, arch and mid-abdominal aorta. Date of birth and age at death ascertained from family pedigrees were used to perform life table analysis and estimate survival. RESULTS. Aortic root and arch diameters were significantly greater in patients with a family history of severe cardiovascular disease than in patients without such a family history. Of subjects in the highest quartile for aortic size, > 80% had such a family history in contrast to < 10% of those in the lowest quartile (chi-square 57.37, p < 0.00001). Mean age at death and cumulative probability of survival were significantly lower in patients with such a family history. CONCLUSIONS. Among patients with the Marfan syndrome, aortic dilation is greater and life expectancy shorter in those with a family history of severe cardiovascular manifestations. These data suggest that such a family history is an important risk factor for cardiovascular events in patients with the Marfan syndrome.

This article has been cited by other articles:

				G. Jondeau, D. Detaint, F. Tubach, F. Arnoult, O. Milleron, F. Raoux, G. Delorme, L. Mimoun, L. Krapf, D. Hamroun, et al. Aortic Event Rate in the Marfan Population: A Cohort Study Circulation, January 17, 2012; 125(2): 226 - 232. [Abstract] [Full Text] [PDF]

				F. Alpendurada, J. Wong, A. Kiotsekoglou, W. Banya, A. Child, S. K. Prasad, D. J. Pennell, and R. H. Mohiaddin Evidence for Marfan cardiomyopathy Eur J Heart Fail, October 1, 2010; 12(10): 1085 - 1091. [Abstract] [Full Text] [PDF]

				D. Detaint, L. Faivre, G. Collod-Beroud, A. H. Child, B. L. Loeys, C. Binquet, E. Gautier, E. Arbustini, K. Mayer, M. Arslan-Kirchner, et al. Cardiovascular manifestations in men and women carrying a FBN1 mutation Eur. Heart J., September 2, 2010; 31(18): 2223 - 2229. [Abstract] [Full Text] [PDF]

				A. O. Caglayan and M. Dundar Inherited diseases and syndromes leading to aortic aneurysms and dissections Eur J Cardiothorac Surg, June 1, 2009; 35(6): 931 - 940. [Abstract] [Full Text] [PDF]

				R. E Pyeritz Marfan syndrome: 30 years of research equals 30 years of additional life expectancy Heart, February 1, 2009; 95(3): 173 - 175. [Full Text] [PDF]

				M. G. Keane and R. E. Pyeritz Medical Management of Marfan Syndrome Circulation, May 27, 2008; 117(21): 2802 - 2813. [Full Text] [PDF]

				L. G. Svensson, E. H. Blackstone, J. Feng, D. de Oliveira, A. M. Gillinov, M. Thamilarasan, R. A. Grimm, B. Griffin, D. Hammer, T. Williams, et al. Are Marfan Syndrome and Marfanoid Patients Distinguishable on Long-Term Follow-Up? Ann. Thorac. Surg., March 1, 2007; 83(3): 1067 - 1074. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, A. Vahanian, H. Baumgartner, J. Bax, E. Butchart, R. Dion, G. Filippatos, F. Flachskampf, R. Hall, B. Iung, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology Eur. Heart J., January 26, 2007; (2007) ehl428v1. [Full Text] [PDF]

				Characterization of the inflammatory and apoptotic cells in the aortas of patients with ascending thoracic aortic aneurysms and dissections. J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 671 - 678.

				G. J. Nollen, M. Groenink, J. G.P. Tijssen, E. E. van der Wall, and B. J.M. Mulder Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome Eur. Heart J., July 1, 2004; 25(13): 1146 - 1152. [Abstract] [Full Text] [PDF]

				B. Iung, C. Gohlke-Barwolf, P. Tornos, C. Tribouilloy, R. Hall, E. Butchart, and A. Vahanian Recommendations on the management of the asymptomatic patient with valvular heart disease Eur. Heart J., August 2, 2002; 23(16): 1253 - 1266. [PDF]

				P. N Robinson and M. Godfrey The molecular genetics of Marfan syndrome and related microfibrillopathies J. Med. Genet., January 1, 2000; 37(1): 9 - 25. [Abstract] [Full Text]

				M Groenink, T A J Lohuis, J G P Tijssen, M S J Naeff, R C M Hennekam, E E van der Wall, and B J M Mulder Survival and complication free survival in Marfan's syndrome: implications of current guidelines Heart, October 1, 1999; 82(4): 499 - 504. [Abstract] [Full Text] [PDF]

				M Groenink, L Rozendaal, M S J Naeff, R C M Hennekam, A A M Hart, E E van der Wall, and B J M Mulder Marfan syndrome in children and adolescents: predictive and prognostic value of aortic root growth for screening for aortic complications Heart, August 1, 1998; 80(2): 163 - 169. [Abstract] [Full Text]